Macrodex

Quick links to important sections

Macrodex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macrodex

What is Macrodex? A Foundational Overview

Property Description
Active Ingredient Dextran (Polysaccharide)
Form Solution for Infusion
Pharmacological Class Plasma Volume Expander (PVE)
General Purpose Volume Replacement / Circulatory Support
Origin Synthetic (Derived from Sucrose)

Macrodex: Definition and Pharmacological Classification

Macrodex is the brand name for a sterile, prescription-only medication whose active component is Dextran, a synthetic polysaccharide. It is precisely classified as a Plasma Volume Expander (PVE) and is administered as an intravenous solution (infusion). This product is widely recognized within critical care settings due to its long history of clinical recognition for rapid volume replacement. It is used to increase plasma volume and restore normal blood circulation. This means the medication helps correct low blood volume and stabilize the circulatory system.

Composition and Origin of the Active Ingredient

The core component, Dextran, is a molecule that is manufactured through controlled bacterial processes using sucrose, defining its origin as synthetic. Macrodex is prepared and utilized in two primary clinical variations, Dextran 40 and Dextran 70, categorized by their molecular weight. Dextran 70 is used for volume replacement and maintenance of blood pressure. Dextran functions by increasing the fluid volume within the bloodstream. The medication is a single-ingredient solution prepared in an aqueous solution of saline or dextrose, which serves as the correct base vehicle for safe intravenous delivery.

General Purpose of a Plasma Volume Expander

The general function of a Plasma Volume Expander is to rapidly and effectively restore the necessary amount of fluid circulating within the blood vessels. A typical, neutral use scenario involves managing acute blood loss, such as following a traumatic injury. By substantially increasing the fluid volume and exerting osmotic pressure, Macrodex helps to stabilize the patient’s circulatory dynamics. This critical function supports adequate blood pressure and protects the vascular system and vital organs from failure during periods of acute fluid deficiency.

Regulatory References

  1. MedlinePlus, Dextran 70 and Dextran 40

What side effects are possible with Macrodex?

Possible Side Effects and Safety Information

The most significant safety concern associated with Macrodex (Dextran 70) is the risk of hypersensitivity or anaphylactoid reactions. These reactions can range from mild effects like urticaria (hives) and flushing to severe, life-threatening events such as anaphylactic shock, which may include bronchospasm, severe hypotension, and cardiac arrest. These serious reactions typically occur within the first few minutes of the infusion.


Other Adverse Reactions and Warnings

Adverse effects are also categorized by the physiological system affected:

  • Cardiovascular/Fluid Balance: The rapid expansion of plasma volume can lead to circulatory overload, potentially resulting in pulmonary edema or cardiac distress. Patients must be closely observed for signs of volume excess.
  • Hematologic: Macrodex can interfere with blood coagulation, which may cause a haemorrhagic diathesis or prolonged bleeding, especially at higher doses. It is contraindicated for use with heparin or low molecular weight heparins.
  • Renal/Urinary: Acute renal failure or kidney impairment resulting from tubular damage is a known risk, particularly if the patient is dehydrated or oliguric. Monitoring urinary output is essential during administration.
  • General: Other reported effects include fever, nausea, vomiting, joint pain, and local irritation or swelling at the injection site.

Contraindications and Safety Restrictions

Macrodex is contraindicated in patients with a known hypersensitivity to dextran, severe congestive heart failure, severe bleeding disorders, or severe renal disease resulting in oliguria or anuria. Its use in pregnancy and lactation has not been established and is generally reserved only when the potential maternal benefit outweighs the risks to the fetus or neonate. The patient should be monitored closely, and appropriate resuscitative measures must be immediately available during the initial infusion.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Macrodex

Overdose Scope

Component Official Regulatory Statement
Documented overdose presentations Overexpansion of blood volume resulting in circulatory overload; severe, acute anaphylactic-type reactions; indications of acute kidney injury like oliguria or anuria.
Physiological systems affected (as stated in label) Circulatory (hypotension, cardiac arrest); Pulmonary (pulmonary edema); Renal (acute renal failure); Hematological (hemorrhagic diathesis).
Dose-related or exposure-related factors (if applicable) Risk of rapid vascular overloading is associated with the rate and total volume of administration.
Population-specific overdose notes (if applicable) Increased risk of severe complications exists for patients with compromised cardiac function or pre-existing renal impairment.
Emergency-response statements (as written in official documents) The infusion must be immediately discontinued at the first sign of a reaction; resuscitation equipment must be readily available.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for signs of severe allergic reaction, including wheezing, chest tightness, or swelling of the face or throat.

Overdose Classifications (high-level)

Classification Regulatory Statement
Severity classification (as defined in official documents) Life-threatening outcomes documented, encompassing fatal reactions, severe hypotension, and acute renal failure.
Regulatory basis (EMA / FDA / etc.) Based on official Prescribing Information from the U.S. Food and Drug Administration and monographs published by the National Institutes of Health.
Overdose-context constraints (as defined in official documents) No specific antidote is known; management is limited to symptomatic and supportive treatment.

Resulting overdose structure

Official overdose statements:

  • Overdose may lead to vascular overloading and subsequent development of pulmonary edema or other forms of cardiac distress.
  • The most critical risks documented are fatal reactions, severe hypotension, and cardiac or respiratory arrest linked to acute hypersensitivity.
  • Required procedures involve the immediate discontinuation of the infusion and the administration of an osmotic diuretic if fluid overexpansion symptoms occur.
  • Immediate medical help is mandated for any sign of a severe allergic reaction, such as swelling of the face or throat.
  • Close monitoring for fluid overload and signs of impending renal failure (oliguria) is required during observation.

Connection to the overall overdose profile

Regulatory documents define the Macrodex overdose profile around the dual threats of life-threatening hypersensitivity reactions and severe vascular overloading due to its plasma expansion properties. Official statements strictly mandate the immediate cessation of administration and the prompt seeking of emergency medical assistance upon recognition of specific, severe symptoms like wheezing or swelling. Management is officially restricted to supportive care, targeting the documented complications.

Therapeutic Uses of Macrodex

What Macrodex Treats: Main Uses and Benefits

Macrodex (Dextran) is commonly used across acute care settings to help manage critical situations involving immediate circulatory imbalance and the risk of symptoms related to systemic imbalance.

The core therapeutic function of Dextran is to serve as an adjunctive management for shock and may assist with managing the risk of thromboembolic disorders.


Therapeutic Focus and Symptom Management

This medication is relevant for addressing symptoms resulting from severe, acute fluid loss, such as that caused by major trauma, surgical blood loss, or extensive burns. The key benefit may assist with the supportive restoration of circulating blood volume, which contributes to easing the overall symptom load associated with systemic imbalance.

Macrodex is commonly used in clinical settings where supportive management is needed to help with symptoms related to systemic imbalance that affect circulation. It also may assist with managing the risk of venous thrombosis and pulmonary embolism, providing supportive relief when symptoms interfere with routine activities in post-operative phases. The medication is relevant during phases when symptoms create noticeable physiological strain.


Quick Fact: Relief for Circulatory Distress Macrodex is commonly used in clinical settings that involve acute or unstable symptom patterns and is relevant when short-term symptomatic assistance is needed for volume deficiency.

Regulatory References

  1. DailyMed (NIH/NLM)

Eligibility and Restrictions for Use

Who Can and Cannot Use Macrodex?

Eligibility for Macrodex (Dextran) is strictly defined by regulatory documents, which establish population restrictions and non-eligibility based on pre-existing physiological conditions.


Absolute Non-Eligibility (Contraindicated)

Macrodex must not be used by patients with known hypersensitivity to dextran.

It is also contraindicated in patients with severe congestive heart failure or marked cardiac decompensation due to the risk of vascular overload. Absolute exclusions further include patients with marked hemostatic defects of any type and those with renal disease progressing with severe oliguria or anuria. Pre-existing pulmonary edema is also an explicit contraindication.


Restricted Use and Specific Populations

The drug's safety and effectiveness have not been established in neonates.

Use in older adults requires caution due to the higher likelihood of reduced organ function. For pregnancy, use is only permitted if clearly needed. Caution is also exercised during lactation, as it is not known whether the drug is excreted in human milk. Patients with impaired renal clearance or conditions aggravated by sodium, such as hypertension, require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Macrodex (Dextran 6% w/v in Dextrose)

The official interaction profile is structured around the drug's inherent antithrombotic effects and its influence on hemostasis, as documented in government regulatory sources.

Interaction Scope

Feature Official Regulatory Information
Interacting Medicinal Product Categories Agents with antithrombotic properties that prolong bleeding time and reduce platelet function.
Mechanistic Basis of Interaction Pharmacodynamic interaction based on Macrodex's documented effects of reducing platelet adhesiveness, decreasing aggregation, and potentially activating plasminogen, leading to a prolonged bleeding time.
Interaction-Related Restrictions Use requires caution and careful monitoring in patients with pre-existing untreated bleeding disorders or those with hemostatic defects.

Interaction Classification and Context

  • Interaction Severity Classification: Classified as clinically significant, requiring careful monitoring and caution when used concomitantly with other blood-affecting agents, due to the potential for excessive bleeding.
  • Interaction-Context Constraints: The main constraint is tied to the patient's existing risk factors and the simultaneous use of any substance that affects blood coagulation or platelet function.

This structure establishes that co-administration with other antithrombotic agents poses a risk due to additive pharmacological effects on hemostasis. Consequently, the interaction profile mandates the review of patient history and clinical laboratory data to manage the cumulative risk of hemorrhage.

Mechanism of Action

Macrodex acts through physical and chemical properties within the intravascular plasma space, independent of receptor binding. Its primary mechanism is based on creating a significant Colloid Osmotic Pressure (COP) gradient. The large Dextran molecules are retained in the blood, actively pulling free water from the surrounding tissues into the circulation. This molecular ightarrow systemic cascade results in an immediate increase in plasma volume, which is the key physiological adjustment for circulatory pressure parameters and systemic flow dynamics.

The secondary domain involves altering blood rheology: the resulting hemodilution significantly lowers blood viscosity (resistance to flow). Furthermore, Dextran molecules coat blood cells and the vascular endothelium, enhancing their electronegativity. This repulsion prevents cellular aggregation, resulting in reduced resistance to flow in the microcirculatory pathway. The molecule also influences the hemostasis pathway by modifying platelet surfaces and altering the final structure of the fibrin clot, which further contributes to the fluid properties of the blood and reduces the tendency for cellular aggregation.

Dosage and Administration Information

Official Administration Guidelines for Macrodex

Macrodex (Dextran 40 or Dextran 70) is formulated as a sterile solution for intravenous (I.V.) infusion and must be administered under direct medical supervision. Proper use is defined by weight-based dosing and strict time limits.


Feature Instruction
Route of Administration Intravenous (I.V.) infusion only.
Dosing Schedule Shock: Maximum 20 mL/kg body weight in the first 24 hours, followed by a maximum of 10 mL/kg/day thereafter. Prophylaxis (Dextran 40): 500 mL to 1,000 mL on the day of operation, followed by 500 mL daily for 2–3 days.
Age-Group Administration The dosage for pediatric patients is weight-based, using a maximum total dose of 20 mL/kg in the first 24 hours. Dosing for older adults requires care, generally starting at the lower end of the dose range.
Course Duration Therapy for shock is not to continue beyond five consecutive days. Prophylactic use may continue intermittently for up to two weeks depending on the specific risk.

Special Procedural Conditions

Macrodex must not be administered unless the solution is clear and free of particulate matter. As a procedural requirement, Dextran 1 must be administered immediately prior to the Macrodex infusion. The administration set used must include a filter when infusing the concentrated solution.

The initial infusion rate may be administered rapidly for the first 10 mL/kg in acute shock situations, but the remainder of the dose must be administered slowly.

This protocol ensures the standardized delivery of the solution according to documented procedural steps.

Recent Clinical Evidence

Research evidence / Overview of Studies for Macrodex


Evidence for Use in Acute Low Blood Volume (Hypovolemic Shock)

Macrodex (Dextran) was evaluated in contexts involving acute, severe fluid loss, often referred to as shock or low blood volume (hypovolemia). Research in this area has relied on a mix of historical controlled clinical trials and comparative studies where Dextran was evaluated in adult patients experiencing acute fluid deficiency. Findings describe patterns observed in these studies where the infusion of Dextran was associated with immediate measurements of plasma volume changes and changes in circulatory markers. Systematic reviews indicate that findings regarding long-term patient outcomes, such as survival up to 180 days, have shown patterns where evidence quality varies across studies.

What remains uncertain is how Macrodex compares against the range of other resuscitation fluids used in critical care settings, as many pivotal studies are older. Contemporary comparative evidence is lacking in some areas, and long-term follow-up durations were limited in many of the initial trials.


Evidence for Post-Operative Clot Prevention

Macrodex was evaluated in studies exploring its potential role in managing the risk of blood clots, specifically deep venous thrombosis (DVT) and pulmonary embolism (PE), which are conditions involving periods of heightened symptoms after major surgery. The research was conducted using Randomized Controlled Trials (RCTs) that examined Dextran against various control agents and specific anticoagulants. These trials were primarily evaluated in adult patients undergoing high-risk surgical procedures.

Reports show that studies tracked and described patterns where the frequency of clotting events was monitored in the Dextran group compared to certain controls. A key limitation is that evidence quality varies across studies, and there are often conflicting results when comparing Dextran to various other prophylactic agents. Furthermore, the follow-up durations were limited, typically covering only the initial 10 to 12 days post-surgery.


What Remains Uncertain or Requires Further Research

Scientific reviews indicate several areas where the evidence landscape remains uncertain. Evidence quality varies across studies, and many original pivotal trials are not aligned with modern standards. There is a clear gap in comparative evidence against the range of contemporary agents. Also, data for certain groups remain insufficient, with comparative evidence lacking for the use of Dextran in pediatric populations and during pregnancy.

Key Studies & References

  1. DailyMed: Dextran 40 and Dextran 70 injection (Prescribing Information and Labeling)
  2. MedlinePlus: Dextran 70 and Dextran 40 Injection (Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Macrodex (FAQ)

Q: What does the term 'plasma volume expander' mean in simple terms?

According to official product information, Macrodex is an intravenous fluid used to rapidly and effectively restore the necessary amount of fluid circulating within the blood vessels. This action is intended to support blood pressure and stabilize circulatory dynamics during periods of acute fluid deficiency.

Q: Is Macrodex considered a blood product or a blood substitute?

Official safety warnings state that Macrodex is not a substitute for whole blood or other blood components. It is, however, classified by many medical sources as a plasma substitute or volume expander because it rapidly increases fluid volume in the bloodstream.

Q: What is the high-level difference between Macrodex and a standard saline IV solution?

Official product information indicates that Macrodex is a colloid, meaning it contains large molecules that create osmotic pressure. This action actively pulls fluid into the blood circulation, expanding the plasma volume. This mechanism is different from standard saline solutions (crystalloids), which primarily function as fluid and electrolyte replacement.

Q: How quickly does Macrodex typically start working after administration?

According to official prescribing information, the intended plasma expanding effect starts immediately upon administration of the intravenous infusion.

Q: How long does the effect of Macrodex generally last in the bloodstream?

The volume expansion effect in the bloodstream generally lasts for about three to four hours following administration. The goal is to stabilize circulatory dynamics within this time frame.

Q: After the infusion stops, how long does Macrodex usually stay in the body?

After the infusion stops, the drug is primarily eliminated through the kidneys. Regulatory data indicates the drug's half-life is approximately 40 minutes, and most of the active ingredient is typically excreted in the urine within 24 hours.

Q: Are allergic reactions to Macrodex common or are they considered rare?

Official safety reports acknowledge the risk of severe, life-threatening allergic reactions, known as anaphylactoid reactions. However, evidence indicates that the occurrence of these severe reactions is considered rare.

Q: Is it necessary to check for interactions with common vitamin or mineral supplements?

Official interaction screening suggests that the regulatory profile includes certain common vitamins and mineral supplements. For safety, it is standard practice to disclose all supplements to the healthcare professional prior to receiving Macrodex.

Q: Is Macrodex only administered in hospital or dedicated clinical settings?

It is administered only as an intravenous infusion. Official guidelines require the drug to be used in a hospital or dedicated clinical setting under the direct supervision of medical staff. It is not administered in a home setting.

Q: Does Macrodex contain blood sugar or affect a patient's overall glucose levels?

The solution can be prepared using dextrose, a form of sugar, as the base vehicle. Official safety warnings indicate that solutions containing dextrose can potentially increase blood sugar levels. Patients with diabetes may need close blood sugar monitoring during and after administration.

Q: Is Macrodex the same drug as the iron supplement called Dextran?

While the active ingredient Dextran is the core molecule for both Macrodex and the component found in the separate product Iron Dextran, their uses differ. Macrodex is used only for volume expansion, not for treating iron deficiency.

Q: Is Macrodex suitable for use in patients with severe dehydration?

Official warnings indicate that Macrodex may be used in poorly hydrated patients, but this requires close monitoring. The drug works by shifting fluid from tissues into the blood, and in these cases, additional fluid therapy may be deemed necessary.

Q: What makes Macrodex capable of causing an allergic or hypersensitivity reaction?

Studies and official reports indicate that the allergic (hypersensitivity) reactions are caused by the body's immune system responding to the Dextran molecule itself. These responses are often mediated by the presence of dextran-reactive antibodies.

Q: Are there specific over-the-counter pain relievers that must be disclosed before receiving Macrodex?

Because Macrodex affects hemostasis (the process of blood clotting), any medication that affects bleeding, including some over-the-counter pain relievers, should be disclosed to the healthcare professional before administration. Official guidelines recommend that all such medications be disclosed to the healthcare professional before administration.

Q: Is Macrodex used for managing patients with severe burns?

Yes, the official indications for Macrodex include the adjunctive treatment of shock or impending shock resulting from severe burns.

Q: What is the expected time window for Macrodex to be effective in treating low blood volume (hypovolemia)?

Studies and official information indicate that the therapeutic effect of plasma volume expansion generally lasts for about three to four hours. The duration of effect can vary among individuals.

Q: Is Macrodex a type of steroid or hormone medication?

No. Macrodex is classified as a plasma volume expander, and its active component, Dextran, is a polysaccharide, which is a type of sugar molecule. It is not defined as a steroid or hormone medication in regulatory documents.

Q: Is Macrodex considered an older medicine, and is it still widely used in medical practice today?

Macrodex is an established medicine with a long history of clinical use. Regulatory bodies include it on the WHO Model List of Essential Medicines for specific indications, such as plasma volume expansion and prevention of certain blood clots after surgery.

Q: Does Macrodex affect the concentration of salt or electrolytes in the body?

Macrodex solution prepared with saline contains sodium chloride (salt). Official warnings advise that this formulation may necessitate caution and monitoring for patients who have restrictions on their sodium intake.

How should Macrodex be stored and disposed of?

How to Store and Dispose of Macrodex?

The official storage and handling instructions for Macrodex (Dextran 40 Injection) are defined by government regulatory documents to maintain product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at 20°C to 25°C (68°F to 77°F), defined as USP Controlled Room Temperature.
Protection Protect from freezing. Do not use if crystallization has occurred.
Handling Inspect the solution for clarity and the container for leakage before use.
Child Safety Store this medicinal product out of the sight and reach of children.

Disposal Instructions

Macrodex is provided in a single-dose container. Any portion of the solution that is unused must be discarded after administration. All unused medicinal product, packaging, and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Macrodex found in:

A-Z Index: